Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: In vitro toxicity and mechanism study

Medical Oncology

Volumn 25, Issue 2, 2008, Pages 161-171

  Chen, Likun ^a   He, Youjian ^a   Huang, He ^a   Liao, Hai ^a   Wei, Weidong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Celecoxib; COX 2; EGFR; Non small cell lung cancer; ZD1839

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTINEOPLASTIC AGENT; BISBENZIMIDE; CYCLOOXYGENASE 2 INHIBITOR; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BISBENZIMIDE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUINAZOLINES; SULFONAMIDES;

EID: 48049110545     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-9015-1     Document Type: Article

References (62)

1. DM Parkin FI Bray SS Devesa 2001 Cancer burden in the year 2000. The global picture Eur J cancer 37 8 S4 S66
2. WL Smith DL DeWitt RM Garavito 2000 Cyclooxygenases: structural, cellular and molecular biology Annu Rev Biochem 69 145 82
3. Koki AT, Jaime L. Celecoxib. A specific COX-2 inhibitor with anticancer properties. Cancer Control March/April 2002;9(2):Supplement: 28-35.
4. AJ Dannenberg NK Altorki JO Boyle 2003 Cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4 605 15
5. M Tsuji RN DuBois 1995 Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endo-peroxide synthase 2 Cell 83 493 501
6. Y Cao AT Pearman GA Zimmerman 2000 Intracellular unesterified arachidonic acid signals apoptosis Proc Natl Acad Sci USA 97 11280 5
7. TA Chan PJ Morin B Vogelstein 1998 Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis Proc Natl Acad Sci USA 95 681 6
8. M Tsujii S Kawano S Tsuji 1998 Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 705 16
9. O KJ Byrne MI Koukourakis A Giatromanolaki 2000 Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer Br J Cancer 82 1427 32
10. M Tsujji S Kawano RN Dubois 1997 Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential Proc Natl Acad Sci USA 94 3330 40
11. M Stolina S Sharma Y Lin 2000 Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis J Immunol 164 361 70
12. O KJ Byrne AG Dalgleish 2000 Evolution, immune response and cancer Lancet 356 1033 4
13. H Sawaoka S Kawano S Tsuji 1998 Effects of NSAIDs on proliferation of gastric cancer cells in vitro J Clin Gastroenterol 27 S47 52
14. S Tomozawa H Nagawa N Tsuno 1999 Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522 Br J Cancer 81 1274 9
15. M Oshima JE Dinchuk SL Kargman 1996 Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition Cell 87 803 9
16. FM Giardiello SR Hamilton AJ Krush 1993 Treatment of colonic and rectal adenomas with sulindac in familial adenomatous N Engl J Med 328 1313 6
17. RE Harris GA Alshafie H Abou-Issa 2000 Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor Cancer Res 60 8 2101 3
18. G Steinbach PM Lynch RK Phillips 2000 The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous N Engl J Med 342 1946 52
19. RE Harris J Beebe-Donk HM Schuller 2002 Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers Oncol Rep 9 693 5
20. A Akhmedkhanov P Toniolo A Zeleniuch-Jacquotte 2002 Aspirin and lung cancer in women Br J Cancer 87 49 53
21. T Hida K Kozaki H Muramatsu 2000 Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines Clin Cancer Res 6 2006 11
22. CA Diperna RD Bart EM Sievers 2003 Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma J Thorac Cardiovasc Surg 126 4 1129 33
23. T Tanaka PA Delong K Amin 2005 Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery Ann Surg 241 1 168 78
24. N Altorki R Keresztes J Port 2002 Celecoxib(Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer Am Soc Clin Oncol Proc 21 A101
25. I Csiki JD Morrow A Sandler 2005 Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel Clin Cancer Res 11 18 6634 40
26. A Wells 2000 The epidermal growth factor receptor (EGFR)-a new target in cancer therapy Signal 1 4 11
27. JR Woodburn 1999 The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 241 50
28. M Fukuodk S Yano G Gaccone 2002 Final results from a Phase II trial of ZD1839('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1) Proc Am Soc Clin Oncol 21 298a A1188
29. MG Kris RB Natale RS Herbst 2002 A Phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2) Proc Am Soc Clin Oncol 21 292a A1166
30. G Tortora R Caputo V Damiano 2003 Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect Clin Cancer Res 9 1566 72
31. CJ Torrance PE Jackson E Montgomery 2000 Combinatorial chemoprevention of intestinal neoplasia Nat Med 6 1024 8
32. Z Chen X Zhang M Li 2004 Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck Clin Cancer Res 10 5930 9
33. Z Jin 1991 The addictiveness of combined drug treatment Trans Pharmacol Chin Tradit med 2 70 2
34. T Hida Y Yatabe H Achiwa 1998 Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas Cancer Res 58 3761 4
35. L Ermert C Dierkes M Ermert 2003 Immumohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors Clin Cancer Res 9 1604 10
36. DK Petkova C Clelland J Ronan 2004 Overexpression of cyclooxygenade-2 in non-small cell lung cancer Respir Med 98 2 164 72
37. CM Richardson D Richardson DE Swinson 2005 Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer Lung Cancer 48 1 47 57
38. C Lu LC Soria X Tang 2004 Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers J Clin Oncol 22 22 4575 83
39. HC Chang CF Weng 2001 Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells Oncol Rep 8 6 1321 5
40. JA Sánchez Alcázar DA Bradbury L Pang 2003 Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase in-dependent pathways Lung Cancer 40 33 44
41. SY Sun CP Schroeder P Yue 2005 Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations Cancer Biol Ther 4 4 407 13
42. X Liu P Yue Z Zhou 2004 Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells J Natl Cancer Inst 96 23 1769 80
43. N Thatcher A Chang P Parikh 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 9496 1527 37
44. AJ Dannenberg SM Lippman JR Mann 2005 Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention J Clin Oncol 23 2 254 67
45. CM Richardson RA Sharma G Cox 2003 Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy Lung Cancer 39 1 13
46. A Ullrich J Schlessinger 1990 Signal transduction by receptors with tyrosine kinase activity Cell 31 637 43
47. Y Sako S Minoghchi T Yanagida 2000 Single-molecule imaging of EGFR signalling on the surface of living cells Nat Cell Biol 2 168 72
48. DJ Riese 2nd DF Stern 1998 Specificity within the EGF family/ErbB receptor family signaling network Bioessays 20 41 8
49. BM Burgering PJ Coffer 1995 Protein kinase B (c-Akt) in phosphatidylinositol -3-OH kinase signal transduction Nature 376 599 602
50. SK Muthuswamy M Gilman JS Brugge 1999 Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers Mol Cell Biol 19 6845 57
51. W Xie HR Herschman 1995 V-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor J Biol Chem 270 27622 8
52. RJ Coffey CJ Hawkey L Damstrup 1997 Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells Proc Natl Acad Sci USA 94 2 657 62
53. JR Mestre K Subbaramaiah PG Sacks 1997 Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells Cancer Res 57 14 2890 5
54. T Yucel-Lindberg H Ahola J Carlstedt-Duke 1999 Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1beta and epidermal growth factor Biochem Biophys Res Commun 257 2 528 32
55. 2 increases growth and motility of colorectal carcinoma cells J Biol Chem 276 18075 81
56. M Tsujii RN DuBois 1995 Alterations in cellular adehesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase-2 Cell 83 493 501
57. 2 stimulates the growth of colon cancer cells via induction of amphiregulin Cancer Res 63 5218 23
58. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor J Biol Chem 278 35451 7
59. 2 J Biol Chem 277 2614 9
60. K Krysan KL Reckamp H Dalwadi 2005 Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner Cancer Res 65 14 6275 81
61. D Thanos T Maniatis 1995 NF-kappa B: a lesson in family values Cell 80 529 32
62. A Gingery E Bradley A Shaw 2003 Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NF Kb pathways to maintain osteoclast survival J Cell Biochem 89 165 179